Bioxytran (OTCMKTS:BIXT) Posts Quarterly Earnings Results

Bioxytran (OTCMKTS:BIXT) issued its earnings results on Thursday. The company reported ($0.01) EPS for the quarter, Zacks reports.

Bioxytran Trading Up 16.7 %

BIXT stock opened at $0.15 on Friday. Bioxytran has a 1-year low of $0.06 and a 1-year high of $0.21. The stock has a market cap of $12.96 million, a price-to-earnings ratio of -14.70 and a beta of 0.98. The company’s 50 day moving average is $0.11 and its 200 day moving average is $0.10.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.